Blue Jet sets a three-year, ₹1,000 cr timeline for its Vizag pivot
Management outlined a plan to build a greenfield facility while chasing 20 RFPs in the high-growth GLP-1 market. Two products are targeted for launch this fiscal year.
— 1 earlier story on Blue Jet Healthcare Ltd. →What's new
- Blue Jet confirmed a three-year timeline for its ₹1,000 cr Vizag greenfield expansion.
- The company is targeting two GLP-1 products for commercialization in FY27.
- Management said prior-quarter destocking pressure is normalizing, with shipments improving.
Why this matters
The call shifted Blue Jet’s story from a post-destocking recovery to a funded growth strategy. The ₹1,000 cr capex is the bet, but the balance sheet has ₹400 cr in liquid assets and no debt to support it. The critical test is converting the 20 GLP-1 RFPs into revenue.
What we're watching
- Commercialization of the first two GLP-1 products in FY27.
- Revenue normalization in the core intermediates segment.
- Execution on the Mahad Unit 3 backward-integration project.
The full read
Blue Jet Healthcare’s Q4 call put a three-year timeline on its ₹1,000 crore greenfield bet in Vizag. The expansion is the centerpiece of a pivot toward higher-value work, led by a push into GLP-1 intermediates. The company is chasing 20 active RFPs, with two products targeted for launch this fiscal year. That is the forward story. The backward-looking update is simpler: destocking that pressured revenue in prior quarters is normalizing, and shipments are picking up. Near term, Blue Jet expects 3-4 new product launches in its contrast media segment and benefits from a backward integration project at its Mahad Unit 3 site. The company is funding this cycle with ₹400 crore in liquid assets and no debt. The open question is execution: converting a pipeline of RFPs into signed contracts.
Questions answered
- What is the scale and timeline for the Vizag expansion?
- Blue Jet is executing a ₹1,000 crore greenfield expansion in Vizag that it expects to complete over the next three years.
- How is the company positioning itself in the GLP-1 market?
- Blue Jet is pursuing 20 active RFPs for GLP-1 linked intermediates and peptide building blocks. Two of these products are targeted for commercialization in the current fiscal year.
- What was the key operational update on current business?
- Management said revenue pressure from inventory destocking in prior quarters is normalizing and shipment trends are improving.
- Can the company fund this expansion plan?
- Yes, Blue Jet is debt-free and holds ₹400 crore in liquid assets, providing the balance sheet capacity to support its capital expenditure cycle.
Story so far
All notes on BLUEJET →- 29 May 2026 · 6:30 PM IST Blue Jet sets a three-year, ₹1,000 cr timeline for its Vizag pivot
- 5d ago Blue Jet Healthcare drops its ₹1,000 cr Vizag project